Cyclo-oxygenase-2 inhibitors. Rationale and therapeutic potential for Alzheimer's disease

Drugs and Aging

Volumn 17, Issue 1, 2000, Pages 1-11

  McGeer, Patrick L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ALZHEIMER DISEASE; ARTHRITIS; CELL PROTECTION; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HUMAN; INFLAMMATION; NERVE CELL; PRIORITY JOURNAL; REVIEW;

EID: 0033927533     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200017010-00001     Document Type: Review

References (52)

1. 1. McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 1995; 21: 195-218
2. 2. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiological studies. Neurology 1996; 47: 425-32
3. 3. Stewart WF, Kawas C, Corrada M, et al. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997 March; 48: 626-32
4. 4. Robitaille A. Improved nonsteroidal anti-inflammatories. Can J Contin Med Educ 1998 July: 85-97
5. 5. Steering Committee of the Physicians' Health Study Research Group. Preliminary report: findings from the aspirin component of the ongoing physicians' health study. N Engl J Med 1988; 318: 262-4
6. 6. Lane NE. Pain management in osteoarthritis: the role of COX-2 inhibitors. J Rheumatol 1997; 24 Suppl. 49: 20-4
7. 7. Lipsky PE, Isakson PC. Outcome of specific COX-2 inhibition in rheumatoid arthritis. J Rheumatol 1997; 24 Suppl. 49: 9-14
8. 8. Wilcox CM, Shalek KA, Cotsonsis G. Striking prevalence of over the counter nonsteroidal anti-inflammatory drug use in patients with upper gastrointestinal hemorrhage. Arch Intern Med 1994; 154(1): 42-6
9. 9. Mackenzie IRA, Munoz DG. Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology 1998 April; 50: 986-90
10. 10. Mackenzie IRA. Anti-inflammatory drugs and Alzheimer type pathology in aging. Neurology 2000; 54: 732-4
11. 11. Beard CM. Kokmen E, Kurland LT. Rheumatoid arthritis and susceptibility to Alzheimer's disease [letter]. Lancet 1991; 337: 1426
12. 12. Breitner JCS, Welsh KA, Helms MJ, et al. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging 1995; 16 (4): 523-30
13. 13. Rich JB, Rasmusson DX, Folstein MF et al. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 1995 Jan; 45: 51-5
14. 14. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993 Aug; 43: 1609-11
15. 15. Scharf S, Mander A, Ugoni A, et al. A double-blind, placebo-controlled trial of diclofenac misoprostol in Alzheimer's disease. Neurology 1999 Jul; 53 (1): 197-201
16. 16. Sainali SM, Ingram DM, Talwaker S, et al. Results of a double-blind, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's disease [abstract]. 6th International Stockholm-Springfield Symposium of Advances in Alzheimer Therapy; 2000 Apr 5-8; Stockholm
17. 17. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232-5
18. 18. Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol 1997; 24 Suppl. 49: 15-9
19. 19. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996 Dec 27; 271 (52): 33157-60
20. 20. Hawkey CJ. COX-2 inhibitors. Lancet 1999 Jan 23; 353: 307-13
21. 21. Yasojima K, Schwab C, McGeer EG, et al. Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res 1999; 830: 226-36
22. 22. Morris JK, Richards JS. An E-box region within the prostaglandin endoperoxide synthase-2 (PGS-2) promoter is required for transcription in rat ovarian granulosa cells. J Biol Chem 1996 July 12; 271 (28): 16633-43
23. 23. Morham SG, Langenbach R, Loftin CD, et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995 Nov 3; 83: 473-82
24. 24. Dinchuk JE, Car BD, Focht RJ, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995 Nov 23; 378: 406-9
25. 25. Langenbach R, Morham SG, Tiano HF, et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995 Nov 3; 83: 483-92
26. 26. Wallace JL, Chin BC. New generation NSAIDs: the benefits without the risks. Drugs Today 1997 Jul-Aug; 33 (6): 371-8
27. 27. Schumann P, Touzani O, Young AR, et al. Effects of indomethacin on cerebral blood flow and oxygen metabolism: a positron emission tomographic investigation in the anesthetized baboon. Neurosci Lett 1996; 220: 137-41
28. 28. Reuter BK, Asfaha S, Buret A, et al. Exacerbation of inflammation-associated colonic injury in rats through inhibition of cyclooxygenase-2. J Clin Invest 1996 Nov; 98 (9): 2076-85
29. 29. Kaufmann WE, Andreason KI, Isakson PC, et al. Cyclooxygenases and the central nervous system. Prostaglandins 1997 Sept; 54: 601-24
30. 30. Kaufmann WE, Worley PF, Pegg J, et al. COX-2, a synaptically-induced enzyme, is expressed by excitatory neurons at post-synaptic sites in rat cerebral cortex. Proc Natl Acad Sci U S A 1996 March; 93: 2317-21
31. 31. Adams J, Collaco-Moraes Y, de Belleroche J. Cyclooxygenase-2 induction in cerebral cortex: an intracellular response to synaptic excitation. J Neurochem 1996; 66 (1): 6-13
32. 32. Yamagata K, Andreasson KI, Kaufmann WE, et al. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 1993 Aug; 11: 371-86
33. 33. Baik EJ, Kim EJ, Lee SH, et al. Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus. Brain Res 1999; 843: 118-29
34. 34. Ho L, Osaka H, Aisen PS, et al. Induction of cyclooxygenase (COX)-2 but not COX-1 gene expression in apoptotic cell death. J Neuroimmunol 1998; 89: 142-9
35. 35. Walton M, Sirimanne E, Williams C, et al. Prostaglandin H synthase-2 and cytosolic phospholipase A(2) in the hypoxicischemic brain: role in neuronal survival. Mol Brain Res 1997 Oct 15; 50 (1-2): 165-70
36. 36. Planas AM, Soriano MA, Justicia C, et al. Induction of cyclooxygenase-2 in the rat brain after a mild episode of focal ischemia without tissue inflammation or neural cell damage. Neurosci Lett 1999; 275: 141-4
37. 37. Nakayama M, Uchimura K, Zhu RL, et al. Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia. Proc Natl Acad Sci U S A 1998 Sept 1; 95 (18): 10954-9
38. 38. Nogawa S, Zhang FY, Ross ME, et al. Cyclooxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci 1997 Apr 15; 17 (8): 2746-55
39. 39. Hara K, Kong DL, Sharp FR, et al. Effect of selective inhibitors of cyclooxygenase-2 on temporary focal cerebral ischemia in rats. Neurosci Lett 1998; 256: 53-6
40. 40. Buccellati C, Folco GC, Sala A, et al. Inhibition of prostanoid synthesis protects against neuronal damage induced by focal ischemia in rat brain. Neurosci Lett 1998; 257: 123-6
41. 41. Inoue H, Yokoyama C, Hara S, et al. Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in endothelial cells. J Biol Chem 1995 Oct 20; 270 (42): 24965-71
42. 42. Lacroix S, Rivest S. Effect of acute systemic inflammatory response and cytokines on the transcription of the genes encoding cyclooxygenase enzymes (COX-1 and COX-2) in the rat brain. J Neurochem 1998 Feb; 70 (2): 452-66
43. 43. Cao C, Matsumura K, Yamagata K, et al. Endothelial cells of the rat brain vasculature express cyclooxygenase-2 mRNA in response to systemic interleukin-1 beta: a possible site ofprostaglandin synthesis responsible for fever. Brain Res 1996 Sept 16; 733 (2): 263-72
44. 44. Ichitani Y, Shi T, Haeggstrom JZ, et al. Increased levels of cyclooxygenase-2 mRNA in the rat spinal cord after peripheral inflammation: an in situ hybridization study. Neuroreport 1997 Sept 8; 8 (13): 2949-52
45. 45. Chan CC, Boyce S, Brideau C, et al. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-fura-none]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 1999; 290 (2): 551-60
46. 46. Penning TD, Talley JJ, Bertenshaw ST, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-{5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonam ide (SC-58635, Celecoxib). J Med Chem 1997; 40: 1347-65
47. 47. Engelhardt G, Bogel R, Schnitzer C, et al. Meloxicam: influence on arachidonic acid metabolism. Biochem Pharmacol 1996; 51: 21-8
48. 48. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995; 44: 1-10
49. 49. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclo-oxygenase) iso-enzymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993 March 25; 268 (9): 6610-4
50. 50. Masferrer JL, Zweifel BS, Manning PT, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and nonulcerogenic. Proc Natl Acad Sci U S A 1994 April; 91: 3228-32
51. 51. Landfield PW, Eldridge JC. Increasing affinity of type II corticosteroid binding in aged rat hippocampus. Exp Neurol 1989; 106: 110-3
52. 52. Aisen PS, Davis KL, Berg JD, et al. A randomized controlled trial of prednisone in Alzheimer's disease. Neurology 2000; 54: 588-93